AlgiPharma wins research grant from CFF

AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine. The grant is administered by the Cystic Fibrosis Foundation Therapeutics Inc., a subsidiary of the CFF. The research shall be performed in the United Kingdom.

About the Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, MD, USA, the Foundation funds CF research, has 80 chapter and branch offices throughout the United States, and supports and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
To advance the search for a cure, CFF has invested nearly $230 million in promising scientific research in the pharmaceutical and biotechnology industries since 1998. As a result, the Foundation has nearly 30 potential therapies in its drug discovery and development pipeline. Any one of these could have a profound impact on the lives of people with cystic fibrosis.

For further information, please contact:
Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

April 2011

AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

April 2011